The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
News|Articles|June 23, 2016
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-07-06-2016
- Volume 11
- Issue 7
Dow Launches ETHOCEL HP
Author(s)Pharmaceutical Technology Editors
ETHOCEL HP is a solvent free advanced productivity technology for barrier membrane coating.
Advertisement
Dow Pharma & Food Solutions, a division of Dow Chemical Company, announced the global launch and commercial availability of ETHOCEL High Productivity (HP), a ethylcellulose polymer for multiparticulate and taste-masking applications, designed specifically for use with rotor coater systems. The product is commercially available exclusively through Colorcon Inc, as part of the Dow and Colorcon Controlled Release Alliance, Dow said in a June 21, 2016
Dry coating with ETHOCEL HP offers shorting coating times for barrier membranes, at higher efficiencies, and without the need for solvents. ETHOCEL HP has shown a step improvement in coating time, 70% faster than traditional solvent and aqueous spray coating systems, according to trials conducted by Dow. Removing the solvent from the coating process allows opportunities for cost reduction and improved operation safety, the company noted.
Source:
Articles in this issue
over 10 years ago
Potential Consequences of the CDMO Acquisition Bingeover 10 years ago
Flow Chemistry Discoveries Advance Continuous Processingover 10 years ago
Excipient Quality Essentialsover 10 years ago
CordenPharma Expands Service Offeringsover 10 years ago
Real-time Monitoring Systems for Drug Shipmentsover 10 years ago
Vessel Improves Dissolution Test Resultsover 10 years ago
Pump Designed for Continuous Processing Scale-upover 10 years ago
Juniper Pharma Services Adds Tablet Pressover 10 years ago
Recipharm Expands Serialization Capabilitiesover 10 years ago
Charles River Acquires Blue Stream LaboratoriesAdvertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement